| Wiskott-Aldrich Syndrome
Cutaquig vs Flebogamma DIF 5%
Side-by-side clinical, coverage, and cost comparison for wiskott-aldrich syndrome.Deep comparison between: Cutaquig vs Flebogamma with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFlebogamma has a higher rate of injection site reactions vs Cutaquig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Flebogamma but not Cutaquig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cutaquig
Flebogamma
At A Glance
SC injection
Weekly
Immune globulin (IGSC)
IV infusion
Every 3-4 weeks
Immune globulin (IGIV)
Indications
- Primary immune deficiency disorder
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
- Wiskott-Aldrich Syndrome
Dosing
Primary immune deficiency disorder, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC dose based on pharmacokinetic and clinical response; for patients switching from IGIV, calculate initial weekly dose by dividing monthly IGIV dose by weeks between infusions and multiplying by adjustment factor of 1.30; for patients switching from IGSC, maintain same weekly dose; dosing interval from daily up to every other week.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome 300-600 mg per kg body weight IV every 3-4 weeks; initial infusion rate 0.01 mL/kg/min (0.5 mg/kg/min), increased to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated.
Contraindications
- Previous anaphylactic or severe systemic reaction to subcutaneous administration of human immune globulin or to any component of CUTAQUIG, including Polysorbate 80
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human globulin treatment
- History of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=5%) Local infusion site reactions (redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, cough
Postmarketing Pancytopenia, leukopenia, hemolytic anemia, anaphylactic reaction, hypersensitivity reaction, angioneurotic edema, thromboembolism, Stevens-Johnson syndrome, aseptic meningitis, seizures, cardiac arrest, respiratory failure, pulmonary embolism, acute renal failure, dizziness, nausea, pruritus, fatigue
Most common, adults (>=5%) Headache, pyrexia, pain, injection site reactions, diarrhea, rigors, urticaria, infusion site inflammation
Most common, pediatrics (>=5%) Headache, pyrexia, hypotension, tachycardia, diastolic hypotension, nausea, abdominal pain, diarrhea, pain, vomiting
Postmarketing Hypersensitivity/anaphylaxis, acute renal dysfunction/failure, ARDS, TRALI, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis syndrome, Stevens-Johnson Syndrome, pancytopenia, hemolysis
Pharmacology
Immune globulin replacement; CUTAQUIG supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, with IgG subclass distribution closely proportional to native human plasma, restoring abnormally low IgG levels to the normal range to help prevent infections in primary humoral immunodeficiency.
Flebogamma 5% DIF is an intravenous immune globulin (IGIV) that provides replacement therapy for primary immunodeficiency by supplying a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cutaquig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
Flebogamma
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Cutaquig
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Flebogamma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cutaquig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Flebogamma
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Octapharma IgCares Co-Pay Assistance Program: CutaquigCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Flebogamma.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CutaquigView full Cutaquig profile
FlebogammaView full Flebogamma profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.